Impact of concomitant use of renin–angiotensin system inhibitors on survival in patients with pancreatic ductal adenocarcinoma: a systematic review and meta-analysis

20260 citationsJournal Articlegold Open Access

Authors

Leszek Kraj · Medical University of Warsaw

Paulina Chmiel · The Maria Sklodowska-Curie National Research Institute of Oncology

Alicja Skrobucha · Medical University of Warsaw

Hanna Grabowska · Cardinal Stefan Wyszynski University in Warsaw

Łukasz Szymański · Institute of Genetics and Animal Biotechnology of the Polish Academy of Sciences

Piotr Wysocki · Gdańsk Medical University

Abstract

Our meta-analysis supports the efficacy of renin-angiotensin system inhibitors as concomitant therapy in patients with PDAC. Prospective randomized clinical trials are warranted to validate ACEI/ARB as adjunctive therapy in well-defined PDAC patient populations.

Topics & Keywords

Renin-Angiotensin System Studies Neuroendocrine Tumor Research Advances Pancreatic and Hepatic Oncology Research

UN Sustainable Development Goals

No poverty

Publication Details

Published in: Therapeutic Advances in Medical Oncology

Volume 18, pp. 17588359251404266-17588359251404266

DOI: 10.1177/17588359251404266

Field-Weighted Citation Impact: 0.00